CereCore joins oracle partner network to strengthen healthcare IT and EHR services

The partnership aligns with the launch of Oracle Health’s next-generation electronic health record

Nitinotes secures CE mark for automated suturing platform ‘EndoZip’

Enabling a new era in minimally invasive obesity treatment across Europe

Granules Life Sciences receives first FDA approval for Hyderabad facility

Bristol Myers Squibb prices €5 billion senior unsecured notes offering

The offering is expected to close on November 10, 2025, subject to customary closing conditions

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'

The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases

Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial

While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage

AstraZeneca delivers double-digit growth

The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials

Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies

The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026